Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitafloxacin EBA in Mycobacterium Abscessus
NCT06809413Phase 2Enrolling by invitation
- Sponsor
- Beijing Chest Hospital
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitafloxacin in Mycobacterium abscessus pulmonary disease, sponsored by Beijing Chest Hospital. Primary endpoint: Early bactericidal activity at 14 days. Started Jan 2025; status: enrolling by invitation.
02
Drugs
sitafloxacin
03
Conditions
Mycobacterium abscessus pulmonary disease
Beyond the preview
Go deeper on NCT06809413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809413.